The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance

Blockade of the pro‐fibrotic reaction mediated by the miR‐143/‐145 cluster enhances the responses to targeted therapy in melanoma

(2022) Serena Diazzi et al.   EMBO Molecular Medicine

Hallmarks of Cancer: New Dimensions

(2022) Douglas Hanahan   Cancer Discovery

ZEB1 transcription factor promotes immune escape in melanoma

(2022) Maud Plaschka et al.   Journal for ImmunoTherapy of Cancer

A cellular hierarchy in melanoma uncouples growth and metastasis

(2022) Panagiotis Karras et al.   NATURE

Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures

(2022) Sultana Mehbuba Hossain et al.   Frontiers in Immunology

Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance

(2022) Ana Popovic et al.   Frontiers in Oncology

Pharmacological blockade of TEAD–YAP reveals its therapeutic limitation in cancer cells

(2022) Yang Sun et al.   Nature Communications

Epithelial‐to‐mesenchymal‐like transition events in melanoma

(2021) Dennis Pedri et al.   FEBS Journal

Therapeutic Targeting of the Tumor Microenvironment

(2021) Leire Bejarano et al.   Cancer Discovery

Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma

(2021) Oskar Marin-Bejar et al.   CANCER CELL

Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment

(2021) Alba Nicolas-Boluda et al.   eLife

Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix‐mediated tumor cell adaptation and tolerance to BRAF‐targeted therapy in melanoma

(2021) Ilona Berestjuk et al.   EMBO Molecular Medicine

Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion

(2021) Xiujie Sun et al.   NATURE

Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance

(2020) Jose L. Orgaz et al.   CANCER CELL

Matrix-Targeting Immunotherapy Controls Tumor Growth and Spread by Switching Macrophage Phenotype

(2020) Claire Deligne et al.   Cancer Immunology Research

A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma

(2020) Christophe A. Girard et al.   CANCER RESEARCH

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition

(2020) Jenny H. Lee et al.   Nature Communications

Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies

(2020) Serena Diazzi et al.   Cancers

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance

(2020) Julia Boshuizen et al.   Nature Communications

Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

(2020) Charles Marusak et al.   CLINICAL CANCER RESEARCH

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

(2020) Ryoji Kato et al.   BRITISH JOURNAL OF CANCER

Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis

(2019) Divya Thomas et al.   Molecular Cancer

Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

(2019) Megan M. Tu et al.   Science Advances

The double edge sword of fibrosis in cancer

(2019) Chelsea Chandler et al.   Translational Research

Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer

(2019) Ivy X. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunotherapy of melanoma: facts and hopes

(2019) Sarah A Weiss et al.   CLINICAL CANCER RESEARCH

RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance

(2019) Daniël A. Lionarons et al.   CANCER CELL

Reduced CTL motility and activity in avascular tumor areas

(2019) Yoav Manaster et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway

(2019) M. Rathore et al.   ONCOGENE

Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities

(2019) Florian Rambow et al.   GENES & DEVELOPMENT

The great escape: tumour cell plasticity in resistance to targeted therapy

(2019) Soufiane Boumahdi et al.   NATURE REVIEWS DRUG DISCOVERY

Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells

(2019) S. A. Misek et al.   ONCOGENE

Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery

(2018) Jonas Schnittert et al.   ADVANCED DRUG DELIVERY REVIEWS

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

(2018) Jennifer Tsoi et al.   CANCER CELL

Toward Minimal Residual Disease-Directed Therapy in Melanoma

(2018) Florian Rambow et al.   CELL

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Targeting the tumour stroma to improve cancer therapy

(2018) Kenneth C. Valkenburg et al.   Nature Reviews Clinical Oncology

Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials

(2018) Marsha C. Lampi et al.   Science Translational Medicine

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma

(2017) Paola Falletta et al.   GENES & DEVELOPMENT

Mutual dependence of the MRTF–SRF and YAP–TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics

(2017) Charles T. Foster et al.   GENES & DEVELOPMENT

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition

(2017) Helen L. Young et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma

(2017) Shumei Song et al.   MOLECULAR CANCER THERAPEUTICS

Targeted agents and immunotherapies: optimizing outcomes in melanoma

(2017) Jason J. Luke et al.   Nature Reviews Clinical Oncology

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance

(2017) Yapeng Su et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

(2017) Chunying Song et al.   Cancer Discovery

Framework to function: mechanosensitive regulators of gene transcription

(2016) Megan Finch-Edmondson et al.   CELLULAR & MOLECULAR BIOLOGY LETTERS

Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma

(2016) Andrew J. Haak et al.   MOLECULAR CANCER THERAPEUTICS

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

(2016) Amanpreet Kaur et al.   NATURE

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

(2016) Hong Jiang et al.   NATURE MEDICINE

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

(2016) I. Tirosh et al.   SCIENCE

Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis

(2016) Michael Hölzel et al.   TRENDS IN IMMUNOLOGY

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

(2015) Eishu Hirata et al.   CANCER CELL

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

(2015) Willy Hugo et al.   CELL

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation

(2015) M. H. Kim et al.   EMBO JOURNAL

BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape

(2015) Inna V. Fedorenko et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells

(2015) Molly H. Jenkins et al.   MATRIX BIOLOGY

Therapy-induced tumour secretomes promote resistance and tumour progression

(2015) Anna C. Obenauf et al.   NATURE

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

(2015) Luping Lin et al.   NATURE GENETICS

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

(2015) I V Fedorenko et al.   ONCOGENE

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state

(2015) Annelien Verfaillie et al.   Nature Communications

Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy

(2014) K. Kemper et al.   CANCER RESEARCH

The extracellular matrix modulates the hallmarks of cancer

(2014) M. W. Pickup et al.   EMBO REPORTS

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

(2014) Judith Müller et al.   Nature Communications

The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF 

(2014) M. P. Smith et al.   Cancer Discovery

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

(2013) Rizwan Haq et al.   CANCER CELL

Influence of tumour micro-environment heterogeneity on therapeutic response

(2013) Melissa R. Junttila et al.   NATURE

Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts

(2013) Fernando Calvo et al.   NATURE CELL BIOLOGY

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

(2012) Jennifer Landsberg et al.   NATURE

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Transduction of mechanical and cytoskeletal cues by YAP and TAZ

(2012) Georg Halder et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma

(2012) Maria R. Girotti et al.   Cancer Discovery

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Linking actin dynamics and gene transcription to drive cellular motile functions

(2010) Eric N. Olson et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling

(2009) Kandice R. Levental et al.   CELL